Tags

Type your tag names separated by a space and hit enter

The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
J Psychopharmacol. 2010 Jul; 24(7):981-6.JP

Abstract

Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 +/- 33.1 and 4.2 +/- 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Se Hyun Kim
Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea.
Dong Chung Jung
No affiliation info available
Yong Min Ahn
No affiliation info available
Yong Sik Kim
No affiliation info available

MeSH

AdultAntipsychotic AgentsClozapineDelayed-Action PreparationsDrug Therapy, CombinationFemaleHospitalizationHumansInjectionsMalePatient CompliancePsychiatric Status Rating ScalesRisperidoneSchizophreniaSchizophrenia, ParanoidSchizophrenic PsychologySocial BehaviorTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19942641

Citation

Se Hyun Kim, , et al. "The Combined Use of Risperidone Long-acting Injection and Clozapine in Patients With Schizophrenia Non-adherent to Clozapine: a Case Series." Journal of Psychopharmacology (Oxford, England), vol. 24, no. 7, 2010, pp. 981-6.
Se Hyun Kim , Dong Chung Jung , Yong Min Ahn , et al. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J Psychopharmacol. 2010;24(7):981-6.
Se Hyun Kim, ., Dong Chung Jung, ., Yong Min Ahn, ., & Yong Sik Kim, . (2010). The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. Journal of Psychopharmacology (Oxford, England), 24(7), 981-6. https://doi.org/10.1177/0269881109348174
Se Hyun Kim , et al. The Combined Use of Risperidone Long-acting Injection and Clozapine in Patients With Schizophrenia Non-adherent to Clozapine: a Case Series. J Psychopharmacol. 2010;24(7):981-6. PubMed PMID: 19942641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. AU - Se Hyun Kim,, AU - Dong Chung Jung,, AU - Yong Min Ahn,, AU - Yong Sik Kim,, Y1 - 2009/11/26/ PY - 2009/11/28/entrez PY - 2009/11/28/pubmed PY - 2010/9/18/medline SP - 981 EP - 6 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 24 IS - 7 N2 - Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 +/- 33.1 and 4.2 +/- 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/19942641/The_combined_use_of_risperidone_long_acting_injection_and_clozapine_in_patients_with_schizophrenia_non_adherent_to_clozapine:_a_case_series_ L2 - https://journals.sagepub.com/doi/10.1177/0269881109348174?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -